

Claims:

1. The use of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a H₃ receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors.
2. The use of a H₃ receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor.
3. The use of a H₃ receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition useful for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor.
4. The use according to any of claims 2-3 wherein the serotonin reuptake inhibitor is used for the treatment of depression, anxiety disorders and other affective disorders, including generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder or social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to a SRI.
5. The use of a compound, which is a serotonin reuptake inhibitor, and a compound, which is a H₃ receptor antagonist, inverse agonist or partial agonist, for the preparation of a pharmaceutical composition for use in the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder,

post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors.

5

6. The use according to any of claims 1-5 wherein a selective serotonin reuptake inhibitor is used.

10

7. The use according to any of claims 1-6 wherein a compound, which is selective for the H₃ receptor, is used.

8. The use according to any of claims 1-7 wherein an antagonist or an inverse agonist at the H₃ receptor is used.

15

9. The use according to any of claim 1-8 wherein a H₃ receptor antagonist is used.

20

10. The use according to any of claims 1-9 wherein the SRI is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, duloxetine, vilazodone, nefazodone, imipramine, femoxetine and clomipramine.

25

11. The use according to any of claims 1-10 wherein the H₃ receptor ligand is selected from Thioperamide, Ciproxifan, Iodophenpropit, GR 175737, Iodoproxyfan, Proxifan, Perceptin, JB 98064, VUF 9153, A 304121, ABT923, ABT 834, A 923, A 320436, A 331440, A 349413, A 349821, A 417022, A 423579, A 424835, A 431404, AQ 0145, FUB 181, FUB 360, FUB 407, FUB 637, FUB 836, GR 168320, GSK 189254A, GSK 207040A, GT 2016, GT 2104, GT 2209, GT 2212, GT 2227, GT 2232, GT 2390, GT 2349, GT 2355, GT 2394, Imoproxifan, Impentamine, JNJ 5207852, NNC 0038 0000 1049, NNC 0038 0000 1202, SCH 50971, SCH 79687, UCL 1199, UCL 1283, UCL 1390, UCL 1409, UCL 1860, UCL 1972, UCL 2065, UCL 2138, UCL 2173, UCL 2283, Verongamine, VUF 4163, VUF 5000, VUF 5182.

30

12. A pharmaceutical composition comprising a compound, which is a serotonin reuptake inhibitor, and another compound, which is a H₃ receptor antagonist, inverse agonist or partial agonist, and optionally pharmaceutically acceptable carriers or diluents.

5

13. A pharmaceutical composition according to claim 12 wherein the serotonin reuptake inhibitor used is a selective serotonin reuptake inhibitor.

14. A pharmaceutical composition according to any of claims 12-13 wherein the H₃ antagonist, inverse agonist or partial agonist is selective for the H₃ receptor.

10

15. A pharmaceutical composition according to any of claims 12-14, wherein the H₃ ligand is a H₃ receptor antagonist.

16. A pharmaceutical composition according to any of claims 12-15 characterized in that the serotonin uptake inhibitor is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, duloxetine, vilazodone, nefazodone, imipramine, femoxetine and clomipramine.

15

17. A pharmaceutical composition according to any of claims 12-16 characterized in that the H₃ ligand is selected from Thioperamide, Ciproxifan, Iodophenpropit, GR 175737, Iodoproxyfan, Proxifan, Perceptin, JB 98064, VUF 9153, A 304121, ABT923, ABT 834, A 923, A 320436, A 331440, A 349413, A 349821, A 417022, A 423579, A 424835, A 431404, AQ 0145, FUB 181, FUB 360, FUB 407, FUB 637, FUB 836, GR 168320, GSK 189254A, GSK 207040A, GT 2016, GT 2104, GT 2209, GT 2212, GT 2227, GT 2232, GT 2390, GT 2349, GT 2355, GT 2394, Imoproxifan, Impentamine, JNJ 5207852, NNC 0038 0000 1049, NNC 0038 0000 1202, SCH 50971, SCH 79687, UCL 1199, UCL 1283, UCL 1390, UCL 1409, UCL 1860, UCL 1972, UCL 2065, UCL 2138, UCL 2173, UCL 2283, Verongamine, VUF 4163, VUF 5000, VUF 5182.

20

25

30

18. A pharmaceutical composition according to any of claims 12-17, which is adapted for simultaneous administration of the active ingredients.

19. A pharmaceutical composition according to claim 18 wherein the active ingredients are contained in the same unit dosage form.

5 20. A pharmaceutical composition according to any of claims 12-17 which is adapted for sequential administration of the active ingredients.

21. The pharmaceutical composition according to any of claims 18 or 20 wherein the active ingredients are contained in discrete dosage forms.

10

22. A method for the identification of compounds useful for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as
15 bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors, comprising, in any order:

- 20 (a) measuring the ability of test compounds to inhibit serotonin reuptake and selecting the compounds that have an IC_{50} value below 50 nM;
(b) measuring the affinity of test compounds to the H_3 receptor and selecting the compounds,

and thereafter measuring the efficacy of the selected compounds at the H_3 receptor and selecting the compounds which are antagonists, inverse agonists or partial
25 agonists at the receptor.

23. A method according to claim 22 wherein the compound has an affinity in step (b) of less than 50 nM;

30 24. A method according to any of claims 22 and 23, wherein the compound has an affinity in step (b) of less than 10 nM:

25. A compound identified according to any of the claims 22-24.